This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.18% per year. These returns cover a period from January 1, 1988 through January 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Zynex Inc. (ZYXI) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -76.47% and 12.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q3 Earnings Match Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 0% and 0.84%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 125% and 1.02%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 300% and 6.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 5.26% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Does Zynex Inc. (ZYXI) Have the Potential to Rally 65% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Zynex Inc. (ZYXI) points to a 65.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zynex Inc. (ZYXI) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 8.33% and 0.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 14.29% and 0.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q1 Earnings Miss Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -40% and 0.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 21.05% and 1.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Q3 Earnings Top Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 30.77% and -1.79%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe Zynex Inc. (ZYXI) Could Rally 87%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Zynex Inc. (ZYXI) points to an 86.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zynex Inc. (ZYXI) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 14.29% and -0.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zynex Inc. (ZYXI) Stock Jumps 6.5%: Will It Continue to Soar?
by Zacks Equity Research
Zynex Inc. (ZYXI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zynex Inc. (ZYXI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zynex Inc. (ZYXI) delivered earnings and revenue surprises of 0.00% and 2.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zynex (ZYXI) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zynex's (ZYXI) April orders down approximately 35% from the January and February average. This may have impacted its Q2 earnings.
Agios Gets Orphan Drug Tag for Mitapivat to Treat Thalassemia
by Zacks Equity Research
The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing patients with thalassemia. Stock rises in after-hours trading.
Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex
by Zacks Equity Research
Zacks.com featured highlights include: ThermoGenesis, Minerva, Sprout Social, Black Diamond and Zynex
Top Stock Picks for Week of May 11, 2020
by Panel Of Zacks Experts
Two Medical Products Stocks with Recent Price Strength.
5 Stocks With Recent Price Strength Amid Disappointing Data
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Trump Pushes for US-Made Medical Products: 4 Winners
by Ritujay Ghosh
An executive order to address the lack of medical product manufacturing in the United States could in a way boost manufacturing and sales of home-grown goods.
Top Ranked Momentum Stocks to Buy for May 5th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 5th
New Strong Buy Stocks for May 4th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Will Zynex Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Zynex
Zynex Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Zynex has been struggling lately, but the selling pressure may be coming to an end soon.